Potential solutions for manufacture of CAR T cells in cancer immunotherapy

Ulrich Blache (), Georg Popp, Anna Dünkel, Ulrike Koehl and Stephan Fricke
Additional contact information
Ulrich Blache: Fraunhofer Institute for Cell Therapy and Immunology (IZI)
Georg Popp: Fraunhofer Institute for Cell Therapy and Immunology (IZI)
Anna Dünkel: Fraunhofer Institute for Cell Therapy and Immunology (IZI)
Ulrike Koehl: Fraunhofer Institute for Cell Therapy and Immunology (IZI)
Stephan Fricke: Fraunhofer Institute for Cell Therapy and Immunology (IZI)

Nature Communications, 2022, vol. 13, issue 1, 1-5

Abstract: CAR T cell therapy is an effective cancer treatment, but biological and manufacturing hurdles hamper its broad breakthrough. Although the first step towards automated manufacture of CAR cells has been taken, new technologies are needed to enable the treatment of large patient groups.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32866-0 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32866-0

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32866-0

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().